Zogenix (NASDAQ: ZGNX) is one of 496 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Zogenix to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Valuation & Earnings
This table compares Zogenix and its competitors gross revenue, earnings per share (EPS) and valuation.
Zogenix’s competitors have higher revenue and earnings than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings for Zogenix and its competitors, as reported by MarketBeat.
||Strong Buy Ratings
Zogenix currently has a consensus target price of $54.00, indicating a potential upside of 20.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 36.94%. Given Zogenix’s competitors higher probable upside, analysts clearly believe Zogenix has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
47.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 5.0% of Zogenix shares are held by insiders. Comparatively, 15.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Zogenix and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Zogenix has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Zogenix’s competitors have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.
Zogenix competitors beat Zogenix on 7 of the 12 factors compared.
Zogenix Company Profile
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.